Arvinas Crecimiento futuro

Future controles de criterios 2/6

Arvinas se prevé un crecimiento anual de los beneficios y los ingresos de 5% y 31% respectivamente. Se prevé que el BPA sea de grow en 10.1% al año. Se prevé que la rentabilidad de los fondos propios sea de -507.7% en 3 años.

Información clave

27.1%

Tasa de crecimiento de los beneficios

31.5%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	20.9%
Tasa de crecimiento de los ingresos	35.6%
Rentabilidad financiera futura	-49.0%
Cobertura de analistas	Good
Última actualización	12 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Arvinas: Behind The Huge Rally

Mar 03

What Arvinas, Inc.'s (NASDAQ:ARVN) 28% Share Price Gain Is Not Telling You

Feb 25

News Flash: Analysts Just Made A Notable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts

Aug 13

Arvinas a buy at Piper Sandler following failure of Sanofi breast cancer treatment

Aug 19

Arvinas: Still Holding, Just Not Buying More

May 23

Arvinas: One Of The Most Interesting Science-Heavy Emerging Biopharma

Feb 07

Arvinas: 2022 Is Full Of Catalysts For This Protein Degrader Pioneer

Nov 19

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:ARVN - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	291	-319	-314	-260	14
12/31/2025	217	-336	-330	-285	18
12/31/2024	161	-327	-264	-338	17
12/31/2023	79	-367	-351	-348	N/A
9/30/2023	159	-295	-340	-336	N/A
6/30/2023	158	-298	-323	-318	N/A
3/31/2023	137	-301	-313	-308	N/A
12/31/2022	131	-282	-280	-273	N/A
9/30/2022	127	-253	-246	-238	N/A
6/30/2022	103	-233	503	510	N/A
3/31/2022	75	-213	536	541	N/A
12/31/2021	54	-191	555	559	N/A
9/30/2021	23	-180	562	566	N/A
6/30/2021	21	-164	-142	-138	N/A
3/31/2021	21	-139	-118	-112	N/A
12/31/2020	26	-119	-96	-90	N/A
9/30/2020	24	-99	-83	-77	N/A
6/30/2020	47	-86	-59	-53	N/A
3/31/2020	45	-78	-52	-45	N/A
12/31/2019	43	-70	-47	-41	N/A
9/30/2019	42	-65	-42	-37	N/A
6/30/2019	15	-173	-54	-50	N/A
3/31/2019	14	-179	-51	-48	N/A
12/31/2018	14	-240	-19	-16	N/A
9/30/2018	13	-233	22	24	N/A
6/30/2018	12	-114	26	28	N/A
3/31/2018	10	-98	30	31	N/A
12/31/2017	8	-29	4	5	N/A
12/31/2016	7	-12	N/A	-19	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: ARVN se prevé que siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: ARVN se prevé que siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: ARVN se prevé que siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: ARVNSe prevé que los ingresos de la empresa (31% al año) crezcan más deprisa que los del mercado US (8.1% al año).

Ingresos de alto crecimiento: ARVNSe prevé que los ingresos de la empresa (31% al año) crezcan más deprisa que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: ARVN se prevé que no sea rentable en 3 años.

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Arvinas Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus EPS estimates upgraded to US$5.13 loss

Consensus EPS estimates upgraded to US$5.76 loss

Price target decreased by 7.5% to US$55.82

Consensus estimates of losses per share improve by 13%

Price target decreased by 7.6% to US$55.80

Price target decreased by 10.0% to US$60.38

Recent updates

Arvinas, Inc., Annual General Meeting, May 29, 2024

Consensus EPS estimates upgraded to US$5.13 loss

Arvinas, Inc. Appoints Noah Berkowitz as Chief Medical Officer and A Member of the Executive Committee

Arvinas: Behind The Huge Rally

Full year 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates upgraded to US$5.76 loss

Arvinas, Inc. announced that it has received $349.999871 million in funding from a group of investors

What Arvinas, Inc.'s (NASDAQ:ARVN) 28% Share Price Gain Is Not Telling You

Arvinas, Inc. Announces Chief Financial Officer Changes

Arvinas, Inc. Announces Chief Financial Officer Changes

Arvinas, Inc. and Pfizer Inc. Announces That the U.S. Food and Drug Administration Has Granted Fast Track Designation for the Investigation of Vepdegestrant (Arv-471) for Monotherapy

Arvinas, Inc. Announces Appointment of Jared Freedberg as General Counsel

Arvinas, Inc. and Pfizer Inc. Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®?) and Plans to Expand Vepdegestrant Development Program

Price target decreased by 7.5% to US$55.82

New minor risk - Share price stability

Consensus estimates of losses per share improve by 13%

Price target decreased by 7.6% to US$55.80

New minor risk - Shareholder dilution

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 10.0% to US$60.38

Arvinas, Inc. Announces the Presentation of Interim Data from the its Phase 1/2 Clinical Trial for Bavdegalutamide

Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023

Consensus revenue estimates increase by 17%

News Flash: Analysts Just Made A Notable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Arvinas and Pfizer Wins Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant

Arvinas and Pfizer Wins Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant

New minor risk - Share price stability

Arvinas, Inc. Announces Changes to its Board of Directors

Arvinas, Inc. Announces Interim Data from Phase 1/2 Dose Escalation and Expansion Trial of ARV-766

Consensus revenue estimates increase by 10%, EPS downgraded

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

There's Reason For Concern Over Arvinas, Inc.'s (NASDAQ:ARVN) Price

Consensus EPS estimates fall by 12%

Calculating The Fair Value Of Arvinas, Inc. (NASDAQ:ARVN)

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Arvinas Announces Changes to Its Board of Directors

Arvinas, Inc. Announces in Post-Hoc Analysis from Phase 2 Cohort Expansion Portion (VERITAC) of Phase 1/2 Study with ARV-471 Expects VERITAC-2 Phase 3 Trial Population Achieve Clinical Benefit Rate of 62.5%

Price target decreased to US$83.90

Arvinas, Inc. Announces Initial Results from Phase 2 Cohort Expansion Portion (VERITAC) of Phase 1/2 Study with ARV-471 Co-Developed with Pfizer Inc

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Arvinas, Inc. Appoints Paul McInulty as Senior Vice President, Regulatory Affairs

Arvinas initiated Overweight at Barclays on attractive therapeutic platform

Arvinas a buy at Piper Sandler following failure of Sanofi breast cancer treatment

Arvinas, Inc. Announces Changes to its Board of Directors

Chief Medical Officer exercised options and sold US$69k worth of stock

Arvinas, Inc. Appoints Lisa Sinclair as Senior Vice President, Corporate Operations

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Arvinas, Inc. Appoints John Northcott as Chief Commercial Officer

Arvinas: Still Holding, Just Not Buying More

Consensus EPS estimates fall by 12%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new directors

CFO & Treasurer exercised options and sold US$810k worth of stock

Chief Scientific Officer exercised options to buy US$226k worth of stock.

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Consensus forecasts updated

Chief Scientific Officer notifies of intention to sell stock

Arvinas, Inc. Announces Completed Phase 1 and Interim Phase 2 ARDENT Data for Bavdegalutamide (ARV-110), A Novel PROTAC® Degrader Targeting the Androgen Receptor

Arvinas, Inc. Announces New Data from Completed Phase 1 Dose Escalation and Ongoing Phase 2 Ardent Expansion Cohort with Novel PROTAC® Degrader Bavdegalutamide (ARV-110) to Present At 2022 ASCO GU Meeting

Arvinas: One Of The Most Interesting Science-Heavy Emerging Biopharma

Independent Director exercised options and sold US$793k worth of stock

Chief Medical Officer exercised options and sold US$782k worth of stock

CFO & Treasurer notifies of intention to sell stock

Independent Director recently sold US$24m worth of stock

Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer

Consensus forecasts updated